Medincell to Participate in Two American Biotech Conferences in June 2026
Medincell announced on Tuesday that its management will participate in two major American biotech conferences in June. These presentations come as the company advances in the development of long-acting injectable treatments, with several candidates in clinical and commercial phases.
Participation in Jefferies and Evercore Conferences
Christophe Douat, CEO, and Grace Kim, Chief Strategy Officer U.S. Finance, will speak at the Jefferies Annual NY Biotech Conference, scheduled from June 2 to June 4, 2026, in New York. Their presentation is set for June 4 at 9:55 AM. The group will also be represented at the Evercore Summer Symposium, which will take place from June 22 to June 24, 2026, in Newport, Rhode Island. Investors interested in appointments during this second conference are invited to contact the organization or Medincell directly.
Portfolio of Candidates in Development
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Medincell is developing treatments based on its proprietary Bepo technology, which controls the release of a drug at a therapeutic level for several days, weeks, or months through a subcutaneous or local injection of a fully bioresorbable depot. Risperidone LAI, the first treatment using this technology, received FDA approval for schizophrenia in April 2023 and for bipolar I disorder in October 2025. It is marketed in the United States by Teva under the name Uzedy. Teva submitted an application to the FDA in December 2025 for a monthly formulation of Olanzapine LAI for the treatment of schizophrenia. The FDA accepted this file on February 20, 2026.
SectorSanté · Biotechnologies · Big pharma›Biotechnologie
Context
Period
Period: 9M 2025
Guidance from the release
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
